Author:
Kim Do Hyoung,Cho AJin,Park Hayne Cho,Kim Bo Yeon,Lee Miri,Kim Gui Ok,Kim Jinseog,Lee Young-Ki
Abstract
AbstractRoutine laboratory tests are regularly performed in patients undergoing maintenance hemodialysis (HD) to detect anemia, chronic kidney disease-mineral bone disorders, and cardiovascular disease. More frequent laboratory tests may be associated with better outcomes. However, there is little evidence supporting a specific monitoring interval. This study evaluated the impact of regular laboratory testing on mortality in Korean patients undergoing maintenance HD. We used HD quality assessments, and National Health Insurance Service claims data from October to December 2015. In HD quality assessment, 22 tests are recommended every 1–6 months. A total of 34,950 patients were divided into two groups based on the regularity of laboratory testing. A Cox proportional hazards model was used to assess the effects of regular laboratory tests on patient mortality during a mean follow-up duration of 53.7 months. The proportion of patients with and without regular laboratory testing was 85.6% (n = 29,914) and 14.4% (n = 5036), respectively. Patients who underwent regular laboratory testing had a longer dialysis duration, lower serum phosphorus levels and diastolic blood pressure, and higher hemoglobin and single-pool Kt/V levels than those who did not. After adjusting for demographic and clinical parameters, regular laboratory testing independently reduced mortality risk (hazard ratio, 0.90; 95% confidence interval 0.85–0.95; P < 0.001). Regular laboratory testing was associated with a decreased mortality risk among patients undergoing HD. Management of end-stage kidney disease-related complications based on laboratory tests can improve survival.
Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Silver, S. A. et al. Routine laboratory testing every 4 versus every 6 weeks for patients on maintenance hemodialysis: A quality improvement project. Am. J. Kidney Dis. 73, 496–503. https://doi.org/10.1053/j.ajkd.2018.10.008 (2019).
2. Thomas, A. et al. the frequency of routine blood sampling and patient outcomes among maintenance hemodialysis recipients. Am. J. Kidney Dis. 75, 471–479. https://doi.org/10.1053/j.ajkd.2019.08.016 (2020).
3. Drueke, T. B. & Parfrey, P. S. Summary of the KDIGO guideline on anemia and comment: Reading between the (guide)line(s). Kidney Int. 82, 952–960. https://doi.org/10.1038/ki.2012.270 (2012).
4. Kidney Disease: Improving Global Outcomes, CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl. 76, S1–S130. https://doi.org/10.1038/ki.2009.188 (2009).
5. Erratum: Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. Suppl. 2017(7), 1–59 (2017).